This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Inclusion Criteria:

• Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
• Willing and able to comply with clinic visits and study-related procedures
• Provide signed informed consent

Exclusion Criteria:

• Known hypersensitivity or known allergy that would preclude study drug administration
• Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
• Uncontrolled diabetes mellitus
• History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
• Renal failure, dialysis, or history of renal transplant
• Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
• Pregnant or breastfeeding women

IPD reported in results publication will be shared

Following publication of the final study results.

IPD will be shared with researchers who provide a methodologically sound proposal.